SPG601
Small molecule
SPG601 is one of 36 small molecule programs targeting Fragile X Syndrome. It is currently in development.
1
Indications
2
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
46 competitors in Fragile X Syndrome
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoApproved
Lioresal
NovartisApproved
Namenda
AbbVieApproved
Epidiolex
Jazz PharmaceuticalsApproved
Daliresp
AstraZenecaApproved
Altoprev
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Rilutek
AAzurity Pharmaceuticals
Approved
Minocin
TTriax
Approved
Lithobid
SSolvay Pharmaceuticals
Approved
Clinoril
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for SPG601. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Company
- SSpinogenix